Post

Early signals suggest oral SERD’s potential for more breast cancer patients

The Menarini Group today has announced exploratory results from its EMERALD clinical study that suggest its recently approved oral selective …

US companies drive 2023 drug launches positioned for blockbuster success by 2028

According to GlobalData's Looking Ahead to 2023 – the Future of Pharma report, five drugs set for approval in 2023 …

AION Labs and BioMed X launch sixth challenge for AI-driven drug discovery

Last week, artificial intelligence (AI) innovator AION Labs called for applications for its latest AI-powered startup. In partnership with BioMed …

Catalent CEO drops FY2023 revenue forecast by $450m after “disappointing” quarter

Catalent’s (Somerset, NJ, US) CEO has admitted to the company’s “disappointing” and “poor performance” over the past quarter, and dropped …

Abiogen acquires EffRx to fortify bone disease portfolio

The Italian pharmaceutical company Abiogen Pharma completed an acquisition of a 97.09% stake in the Swiss orphan conditions-focused EffRx Pharmaceuticals …